GSK Seeks High Court Input On IP Safe-Harbor Rule

Law360, New York (March 08, 2012, 9:32 PM ET) -- GlaxoSmithKline PLC asked the U.S. Supreme Court last month to review a decision that upheld Classen Immunotherapies Inc.'s patents for evaluating a vaccine immunization schedule, arguing the Federal Circuit wrongly ruled on a statute covering exemptions meant to protect parties from infringement liability.

GSK said in a petition for writ of certiorari Feb. 28 that the Federal Circuit misread Section 271 of U.S. Code and incorrectly ruled that it was limited to activities conducted to obtain premarketing approval of generic counterparts of patented inventions before patent...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers